Yu-Tao Zhan1, Jing Weng2, Li Li3, Qing Xu2, Xin Song4, Xiao-Xia Guo2. 1. Department of Gastroenterology and Hepatology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People's Republic of China. yutaozhan@263.net. 2. Reproductive Medicine Centre, Capital Medical University, Beijing, 100069, People's Republic of China. 3. Department of Gastroenterology and Hepatology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People's Republic of China. 4. Department of Clinic Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People's Republic of China.
Abstract
AIM: To explore protective effect of probucol on liver injury induced by carbon tetrachloride (CCl4) in rats. METHODS: We used CCl4 to induce a rat model of liver injury. Some of those rats were treated with an oral administration of probucol. Liver function, blood lipid, liver tissue malondialdehyde (MDA), superoxide dismutase (SOD), and degree of liver fibrosis were analyzed. RESULTS: Probucol significantly decreased the elevation of serum aspartate transaminase, total bile acid, alkaline phosphatase and cholesterol, and improved liver histopathological changes (including fatty infiltration, inflammation cell infiltration, and fibrosis), decreased liver tissue MDA level, and increased liver tissue SOD level in liver injury rats. CONCLUSIONS: For the first time, we demonstrated that probucol has protective effect against liver injury in animal experiment. The antioxidant action of probucol may play an important role in its hepatoprotective mechanism. Probucol also can reduce serum cholesterol. Thus, probucol may have the potential use in clinical liver diseases in which oxidative stress may be present, especially for the patients with hypercholesterolemia.
AIM: To explore protective effect of probucol on liver injury induced by carbon tetrachloride (CCl4) in rats. METHODS: We used CCl4 to induce a rat model of liver injury. Some of those rats were treated with an oral administration of probucol. Liver function, blood lipid, liver tissue malondialdehyde (MDA), superoxide dismutase (SOD), and degree of liver fibrosis were analyzed. RESULTS:Probucol significantly decreased the elevation of serum aspartate transaminase, total bile acid, alkaline phosphatase and cholesterol, and improved liver histopathological changes (including fatty infiltration, inflammation cell infiltration, and fibrosis), decreased liver tissue MDA level, and increased liver tissue SOD level in liver injuryrats. CONCLUSIONS: For the first time, we demonstrated that probucol has protective effect against liver injury in animal experiment. The antioxidant action of probucol may play an important role in its hepatoprotective mechanism. Probucol also can reduce serum cholesterol. Thus, probucol may have the potential use in clinical liver diseases in which oxidative stress may be present, especially for the patients with hypercholesterolemia.
Authors: Steven Woon Choy Tsang; Wing Fung Ng; Brian Ping Ying Wu; David Alan Chow; Eric Ting Ho Li; Tak Cheung Wong Journal: J Gastroenterol Hepatol Date: 2006-01 Impact factor: 4.029
Authors: Tsutomu Fujii; Bryan C Fuchs; Suguru Yamada; Gregory Y Lauwers; Yakup Kulu; Jonathan M Goodwin; Michael Lanuti; Kenneth K Tanabe Journal: BMC Gastroenterol Date: 2010-07-09 Impact factor: 3.067